Detalhe da pesquisa
1.
Correction: Robustness of cancer microbiome signals over a broad range of methodological variation.
Oncogene;
43(20): 1579, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38580705
2.
Validation of an Updated Algorithm to Identify Patients With Incident Non-Small Cell Lung Cancer in Administrative Claims Databases.
JCO Clin Cancer Inform;
8: e2300165, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502111
3.
Immuno-Oncology: New Insights into Targets and Therapies.
Surg Oncol Clin N Am;
33(2): 265-278, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38401909
4.
Robustness of cancer microbiome signals over a broad range of methodological variation.
Oncogene;
43(15): 1127-1148, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38396294
5.
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
BMC Cancer;
23(1): 708, 2023 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507657
6.
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.
Nat Commun;
14(1): 2744, 2023 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173324
7.
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Cancer Discov;
13(7): 1556-1571, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068173
8.
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
Cancer Immunol Immunother;
72(7): 2443-2458, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016126
9.
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
J Thorac Oncol;
18(5): 650-656, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36641093
10.
Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions.
Cell;
185(20): 3789-3806.e17, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36179670
11.
Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment.
JCO Precis Oncol;
6: e2100551, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35952324
12.
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer.
Oncologist;
27(9): e739-e747, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35816018
13.
CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer.
Front Immunol;
13: 842653, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35493454
14.
Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy.
Transl Lung Cancer Res;
11(3): 452-461, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35399568
15.
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors.
Clin Cancer Res;
28(1): 95-105, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615718
16.
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Clin Cancer Res;
28(2): 271-278, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716198
17.
Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.
Sci Rep;
11(1): 17324, 2021 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462476
18.
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Cancer;
127(17): 3194-3201, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33882143
19.
Commentary: Induction Immunotherapy: Intriguing Initiative for Investigation.
Semin Thorac Cardiovasc Surg;
33(3): 858-859, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33662553
20.
IMpower 132: Loses Power at the Finish Line.
J Thorac Oncol;
16(4): 512-514, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33781439